Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug
vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...
Diabetes
Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period,...
Sinocare Inc’s Blood Glucose Monitoring System Earns US FDA Approval
Sinocare Inc (SHE: 300298), a Chinese medical device company, has announced that it has received...
Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Novo Nordisk Invests DKK 16 Billion to Expand French Production Facility
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has initiated an expansion of its production facility...
Jiangsu Hengrui Pharmaceuticals’ HR20031 Accepted for Review by China’s NMPA for Type 2 Diabetes
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading Chinese pharmaceutical company, has announced that the National...
Novo Nordisk Commits Over DKK 42 Billion to Expand Chronic Disease Production in Denmark
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, last week announced a substantial plan to...
Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults
Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...
AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third...
Eccogene Secures Exclusive Licensing Deal with AstraZeneca for GLP-1 Agonist ECC5004
Sino-US firm Eccogene Inc. has entered into an exclusive licensing agreement with UK pharmaceutical giant...
Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial
Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its...
Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management
Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...
Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing...
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a...
Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases
Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...
Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study
Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating...